Vanguard Global Advisers
SNDX icon

Vanguard Global Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

Vanguard Global Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$751K Sell
34,371
-3,044
-8% -$63.3K ﹤0.01% 1913
2026
Q1 		$874K Buy
+37,415
New +$813K ﹤0.01% 1727

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Vanguard Global Advisers's SNDX Position: Q2 2026 in Review

Vanguard Global Advisers reduced its Syndax Pharmaceuticals (SNDX) stake by 8.1% in Q2 2026, selling an estimated $63.3K and leaving 34,371 shares worth $751K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Vanguard Global Advisers first reported a position in SNDX in Q1 2026 and has held it in 2 quarters since. The position peaked at $874K in Q1 2026. 240 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Vanguard Global Advisers held 34,371 shares of Syndax Pharmaceuticals worth $751K as of Q2 2026.
  • Vanguard Global Advisers sold 3,044 Syndax Pharmaceuticals shares in Q2 2026, an estimated $63.3K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #1913 holding.
  • Vanguard Global Advisers first reported a position in Syndax Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Syndax Pharmaceuticals position peaked at $874K in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.